Sign in
4

Changes in Ownership

TEVA PHARMACEUTICAL INDUSTRIES LTD Filed Acc 0001209191-20-020163

Executive VP, Global R&D sold 514 shares at $7.16 ($3,682)

  • Executive VP, Global R&D acquired 1,014 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Fridriksdottir Hafrun · Executive VP, Global R&D

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2020-03-17 Exercise or conversion : show line 1 in the form +748 45,808.51 D
2020-03-17 Exercise or conversion : show line 2 in the form +266 46,074.51 D
2020-03-17 Sale : show line 3 in the form −380 $7.16 $2,722 45,694.51 D
2020-03-17 Sale : show line 4 in the form −134 $7.16 $960 45,560.51 D
Open-market sales · 514 sh · avg $7.16 · $3,682

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2020-03-17 Exercise or conversion : show line 5 in the form Restricted Share Units −748 0 D
2020-03-17 Exercise or conversion : show line 6 in the form Restricted Share Units −266 0 D
Loading xslF345X03/doc4.xml…